Arbutus Biopharma Corporation Stock News

Penny stocks to buy for under $5 that have unusual options activity right now. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options Activity appeared first on Penny Stocks to Buy, Picks, N

NEW YORK , Feb. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGNX, BLMN, LTHM, SAND, and ABUS. … Full story available on Benzinga.com

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows:

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali

Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an eff

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent d

Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to announce earnings of ($0.18) per share for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of ($0.23) in []